摘要
目的通过对前列腺癌、前列腺上皮内瘤变、前列腺良性增生及其正常前列腺组织中胸苷激酶1(TK1)和细胞增殖蛋白(MIB-1)标记Ki-67的表达,探讨其对前列腺癌的治疗、预后所起的作用。方法采用免疫组化ABC法检测前列腺癌(PCa)42例,前列腺上皮内瘤变(PIN)35例,良性前列腺增生(BPH)25例和正常前列腺(NP)组织10例中TK1及Ki-67的表达。结果良性前列腺增生及正常前列腺组织中几乎检测不到增殖细胞,在前列腺上皮内瘤中增殖细胞所占的百分比大约为16%～17%,在前列腺癌组织中TK1阳性表达率57.1%,高于Ki-67阳性表达率(47.6%,P<0.05)。结论TK1不仅同Ki-67一样,可作细胞增殖的指标,还因其参与DNA合成及细胞间"旁观者效应"等原因,从而给临床提供治疗及预后方面有价值的参考。
Purpose To identify the expression of TK1 and MIB-1 in prostate carcinoma, prostatic intraepithelial neoplasia （ PIN）, benign prostatic hyperplasia （BPH） and normal prostate tissue in order to get insight into the effects of Ki-67 in the treatment and prognosis of prostate carcinoma. Methods The expression profiles of TK1 and Ki-67 were generated from 42 cases of PCa, 35 PIN, 25 BPH and 10 normal prostate tissues using ABC assay. Results Almost no proliferetive cell was detected in the BPH and normal prostate tissues, about 16% - 17% proliferetive cells in PIN and 57. 1% in prostate carcinoma which was higher than Ki-67＇ s positive expression rate （47.6% , P 〈 0. 05 ）. Conclusions TK1 can be used as the index of cell proliferation, which is the same as the function of Ki-67. And it can also provide valuable references to clinical treatment and prognosis since it participates in DNA synthesis and ＂bystander effect＂ between cells.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2008年第6期664-667,共4页
Chinese Journal of Clinical and Experimental Pathology
作者简介
叶芳萍，女，副主任医师。Tel：（0799）6874086，E-mail：Pxyfp@126．com
